跳至主要内容
临床试验/JPRN-C000000395
JPRN-C000000395已完成4 期

Tenofovir for the treatment of breakthrough hepatitis caused by lamivudine and adefovir dipivoxil-resistant mutants of hepatitis B virus - GLSG,2006,tenofovir

Gunma Liver Study Group (GLSG)0 个研究点目标入组 20 人开始时间: 2012年10月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Allergy to Lamivudine complication of chronic hepatitis coadministration of cytotoxic drugs leucopenia during pregnancy severe liver dysfunction

研究者

发起方
Gunma Liver Study Group (GLSG)

相似试验

已完成
4 期
Entecavir for the treatment of breakthrough hepatitis caused by lamivudine and adefovir dipivoxil-resistant mutants of hepatitis B viruschronic hepaittis B
JPRN-C000000393Gunma Liver Study Group (GLSG)20
进行中(未招募)
不适用
Tenofovir for the treatment of chronic hepatitis B: a study of efficacy and safety in clinical practice in NUC naive or IFN experienced patients. - Ten-B: Tenofovir DF (TDF) in chronic hepatitis B patientschronic hepatitis BMedDRA version: 9.1Level: SOCClassification code 10019805Term: Hepatobiliary disorders
EUCTR2008-003214-94-ITOSPEDALE MAGGIORE DI MILANO (IRCCS)
招募中
不适用
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.Non-cirrhotic, Chronic Hepatitis B
NCT05195450Institute of Liver and Biliary Sciences, India200
进行中(未招募)
1 期
CLINICAL TRIAL WITH PROPHYLACTIC TENOFOVIR FOR HAEMATOLOGICAL CANCER PATIENTS SHOWING A HBc-Ab POSITIVE AND HBs-Ag PATTERN AND TO BE TREATED WITH RITUXIMAB (PREBLIN STUDY)CHRONIC HEPATITIS BMedDRA version: 14.1Level: LLTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestations
EUCTR2011-000905-30-ESRafael Esteban Mur61
Unknown
3 期
Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus AdefovirProportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
NCT03236584Uijeongbu St. Mary Hospital76